-
Company Insights
Innovation and Patenting activity of ImmunityBio Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ImmunityBio Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axitinib SR in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axitinib SR in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axitinib SR in Wet (Neovascular / Exudative)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – M-ceNK in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - M-ceNK in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. M-ceNK in Non-Small Cell Lung Cancer Drug Details: Cellular Immunotherapy...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Monoclonal Antibody Conjugate 3 To Target EGFR For Oncology in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Monoclonal Antibody Conjugate 3 To Target EGFR For Oncology in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Monoclonal Antibody...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Monoclonal Antibody Conjugate 3 To Target EGFR For Oncology in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Monoclonal Antibody Conjugate 3 To Target EGFR For Oncology in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Monoclonal Antibody Conjugate 3...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2809 in Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2809 in Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2809 in Fibrosis Drug Details: VK-2809 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy To Inhibit PD-L1 For Oncology in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy To Inhibit PD-L1 For Oncology in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy To Inhibit PD-L1...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Liposarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Liposarcoma Drug Details: ATX-101 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zanzalintinib Fumarate in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanzalintinib Fumarate in Metastatic Colorectal Cancer Drug Details: Zanzalintinib fumarate (XL-092)...